Hesselink MB - Search Results

1

SLV310, a novel, potential antipsychotic, combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition.

van Hes R, Smid P, Stroomer CN, Tipker K, Tulp MT, van der Heyden JA, McCreary AC, Hesselink MB, Kruse CG. van Hes R, et al. Among authors: hesselink mb. Bioorg Med Chem Lett. 2003 Feb 10;13(3):405-8. doi: 10.1016/s0960-894x(02)00996-4. Bioorg Med Chem Lett. 2003. PMID: 12565939

2

Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[omega-(1H-indol-3-yl)alkyl]piperazines, novel potential antipsychotics combining potent dopamine D2 receptor antagonism with potent serotonin reuptake inhibition.

Smid P, Coolen HK, Keizer HG, van Hes R, de Moes JP, den Hartog AP, Stork B, Plekkenpol RH, Niemann LC, Stroomer CN, Tulp MT, van Stuivenberg HH, McCreary AC, Hesselink MB, Herremans AH, Kruse CG. Smid P, et al. Among authors: hesselink mb. J Med Chem. 2005 Nov 3;48(22):6855-69. doi: 10.1021/jm050148z. J Med Chem. 2005. PMID: 16250644

3

SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.

McCreary AC, Glennon JC, Ashby CR Jr, Meltzer HY, Li Z, Reinders JH, Hesselink MB, Long SK, Herremans AH, van Stuivenberg H, Feenstra RW, Kruse CG. McCreary AC, et al. Among authors: hesselink mb. Neuropsychopharmacology. 2007 Jan;32(1):78-94. doi: 10.1038/sj.npp.1301098. Epub 2006 May 17. Neuropsychopharmacology. 2007. PMID: 16710314

4

In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.

Glennon JC, Van Scharrenburg G, Ronken E, Hesselink MB, Reinders JH, Van Der Neut M, Long SK, Feenstra RW, McCreary AC. Glennon JC, et al. Among authors: hesselink mb. Synapse. 2006 Dec 15;60(8):599-608. doi: 10.1002/syn.20330. Synapse. 2006. PMID: 17001660

5

SONU20176289, a compound combining partial dopamine D(2) receptor agonism with specific serotonin reuptake inhibitor activity, affects neuroplasticity in an animal model for depression.

Michael-Titus AT, Albert M, Michael GJ, Michaelis T, Watanabe T, Frahm J, Pudovkina O, van der Hart MG, Hesselink MB, Fuchs E, Czéh B. Michael-Titus AT, et al. Among authors: hesselink mb. Eur J Pharmacol. 2008 Nov 19;598(1-3):43-50. doi: 10.1016/j.ejphar.2008.09.006. Epub 2008 Sep 17. Eur J Pharmacol. 2008. PMID: 18822282

6

Tonic inhibition by orphanin FQ/nociceptin of noradrenaline neurotransmission in the amygdala.

Kawahara Y, Hesselink MB, van Scharrenburg G, Westerink BH. Kawahara Y, et al. Among authors: hesselink mb. Eur J Pharmacol. 2004 Feb 6;485(1-3):197-200. doi: 10.1016/j.ejphar.2003.11.061. Eur J Pharmacol. 2004. PMID: 14757141

7

Chronic stress decreases the number of parvalbumin-immunoreactive interneurons in the hippocampus: prevention by treatment with a substance P receptor (NK1) antagonist.

Czeh B, Simon M, van der Hart MG, Schmelting B, Hesselink MB, Fuchs E. Czeh B, et al. Among authors: hesselink mb. Neuropsychopharmacology. 2005 Jan;30(1):67-79. doi: 10.1038/sj.npp.1300581. Neuropsychopharmacology. 2005. PMID: 15470372

8

The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat.

Stanhope KJ, Mirza NR, Bickerdike MJ, Bright JL, Harrington NR, Hesselink MB, Kennett GA, Lightowler S, Sheardown MJ, Syed R, Upton RL, Wadsworth G, Weiss SM, Wyatt A. Stanhope KJ, et al. Among authors: hesselink mb. J Pharmacol Exp Ther. 2001 Nov;299(2):782-92. J Pharmacol Exp Ther. 2001. PMID: 11602695

9

Brain distribution of an uncompetitive NMDA receptor antagonist; comparison to its in vitro potency in electrophysiological studies.

Hesselink MB, Parsons CG, Wollenburg C, Danysz W. Hesselink MB, et al. Naunyn Schmiedebergs Arch Pharmacol. 1999 Aug;360(2):144-50. doi: 10.1007/s002109900056. Naunyn Schmiedebergs Arch Pharmacol. 1999. PMID: 10494883

10

The role of probenecid-sensitive organic acid transport in the pharmacokinetics of N-methyl-D-aspartate receptor antagonists acting at the glycine(B)-site: microdialysis and maximum electroshock seizures studies.

Hesselink MB, Smolders H, Eilbacher B, De Boer AG, Breimer DD, Danysz W. Hesselink MB, et al. J Pharmacol Exp Ther. 1999 Aug;290(2):543-50. J Pharmacol Exp Ther. 1999. PMID: 10411561

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

22 results

Search Page

Filters